| Krystal Biotech is a clinical-stage biotechnology company focused on the development of gene therapies to improve the lives of patients living with rare diseases. Co. has developed a gene delivery platform that enables off-the-shelf treatments for serious dermatology and respiratory diseases. Co.'s platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 (HSV-1) that it has optimized for local and repeat gene transfer to epithelial cells. Co.'s main product candidate is Beremagene geperpavec (B-VEC), which is for the treatment of dystrophic epidermolysis bullosa, a rare skin disease caused by missing or mutated mutated type VII collagen protein. The KRYS YTD return is shown above.
The YTD Return on the KRYS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether KRYS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KRYS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.